Clinical Trial

Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
1. Primary Objective: o To evaluate the efficacy of intravenous azithromycin compared with meropenem in the treatment of extensively drug-resistant (XDR) enteric fever. 2. Secondary Objectives: * To evaluate the fever defervescence and Salmonella Typhi eradication * To evaluate the cost-effectiveness of intravenous azithromycin versus meropenem in treating XDR enteric fever. 3. Exploratory Objectives: * To evaluate the drug resistance against intravenous azithromycin versus in treating XDR enteric fever.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-12-31 -> 2027-01-15 2026-05-09
minor Completion pushed: 2025-12-31 -> 2027-01-15 2026-05-09
Trial Details
NCT Number NCT07314281
Lead Sponsor Indus Hospital and Health Network
Conditions Enteric Fever
Enrollment 40 participants
Start Date 2025-04-22
Primary Completion 2027-01-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-08